Hints and tips:
Related Special Reports
...“Private equity continues to have a love affair with pharma-adjacent suppliers,” said Robert Darwin, a partner at law firm Sidley Austin and specialist in life sciences transactions....
...This article has been amended to correct Foresite Capital’s name....
...Dmitry Kuzmin, managing partner of 4Bio Capital, said the past year had brought a “peculiar disconnect” between public markets and appetite for private life sciences investments....
...To attract US investors, Northern Ireland has a new life sciences advisory board chaired by Mark Goldstone, partner in New York-based venture capital firm Eckuity, which specialises in early-stage life science...
...Pfizer is “trying to leverage some of that brand equity that they got the world spinning again”, said Markus Saba, a marketing professor at the University of North Carolina Center for the Business of Health...
Agreement worth up to $1.2bn includes plan for combined flu and Covid shots
...“When we talk about links between climate change and human health, the most obvious thing is extreme heat, and extreme weather events,” says Alan Dangour, head of climate and health at the Wellcome Trust...
...“The climate crisis has numerous impacts on ecosystems, human health, animal health and food production, which also affect AMR,” according to a report titled “Bracing for Superbugs” published last year by...
...“It is true that the science isn’t there yet,” Meg Jones-Monteiro, senior director for health equity at ICCR, told me, arguing that companies should exercise caution in the absence of a clear scientific...
...insurance scheme],” said Robert Przybelski, a geriatrician at UW Health in Madison, Wisconsin, where about 25 patients have been treated with the drug....
...sciences at UC Berkeley....
...University of Singapore’s Saw Swee Hock School of Public Health and has spent years studying malaria in Malaysia....
...The bank said in February that it had raised more than $2bn in seed capital from 27 contributors....
...Several early-stage life sciences investors told the Financial Times the technology was attractive but that the field faced a higher bar for investment than other start-ups....
...McKernan is a former head of Innovate UK and currently a venture partner at life sciences venture capital firm SV Health Investors....
...Silicon Valley’s blue-chip venture capital firm....
...The biotech group’s investors for this funding round include MSD GHIF, an investment arm of US pharma company MSD, along with UK venture capital group IQ Capital....
...But now small-cap life sciences companies are again applying to investors for cash for new projects: drug developers raised $6.2bn in US equity capital markets in January alone....
...Meanwhile, PMI’s reputation is bedevilling its efforts to diversify into health products....
...Opening and running medical practices is capital intensive....
...“The late-stage pipeline is on the thinner side relative to other companies,” said Alessandro Valentini at Causeway Capital, a top 25 investor with a 1 per cent stake....
Forerunners of pharma company tested vaccines at notorious institutions for decades
...The early data helped Compass raise $285mn in a private placement of its shares last August from mainstream biotech funds including $10bn fund RA Capital and Surveyor Capital, an equities business owned...
...Novavax is this year rolling out its second product: a malaria vaccine approved by the World Health Organization, which will help to grow its revenues from $531.4mn last year to a projected $854.2mn this...
...Pfizer and BioNTech will dispute Moderna’s ability to withdraw the pledge when it did, given the World Health Organization did not declare the end of the “global health emergency” until March 2023....
International Edition